Is anything really melhor que Mounjaro — or is that the wrong question entirely?

The biggest myth: one medicine is simply the best for everyone

The question assumes weight-loss treatment works like a product comparison, pick the highest-rated item and buy it. It does not work that way. What clinical trials measure is average weight reduction across large groups of people; what your prescriber considers is you specifically: your BMI, any existing conditions, which medicines you already take, how you feel about injections, and what your daily routine looks like.

That said, the trial evidence is real and worth understanding. SURMOUNT-5, a direct head-to-head study published in the New England Journal of Medicine in 2025, compared tirzepatide against semaglutide 2.4 mg in 751 adults with obesity who did not have type 2 diabetes. Tirzepatide produced meaningfully greater average weight loss over 72 weeks. NICE cited this evidence when recommending tirzepatide in technology appraisal TA1026. That is not a marketing claim, it is the current state of the published evidence.

But evidence averages hide individual variation. Some people in the semaglutide arm of SURMOUNT-5 lost more weight than some in the tirzepatide arm. Biology is not uniform. A prescriber asking about your history is doing exactly the thing a league table cannot do.

Where Wegovy and the new oral tablet stand in the comparison

Wegovy (semaglutide injection) is the other main licensed weight-loss option in the UK, and it has moved on since its original 2.4 mg dose. The MHRA approved a higher 7.2 mg dose, with a dedicated single-dose pen confirmed on 14 April 2026. Trials at 7.2 mg reported around 20.7% average weight reduction over 72 weeks, approaching what tirzepatide achieves at its maintenance doses, though the patient populations and trial designs differ.

Then there is the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. Trial data (OASIS 4, 64 weeks) showed roughly 13.6% average weight loss against placebo, or around 17% among participants who adhered fully throughout. For anyone who dislikes injections or whose circumstances make refrigerated storage difficult, an oral option changes the conversation. The tablet requires no refrigeration and sits easily in a morning routine, before coffee, before breakfast, before anything else.

If you want to understand more about how tirzepatide works at a molecular level before comparing it to other options, our plain-language explainer on tirzepatide covers the dual-receptor mechanism without the jargon, and our guide to tirzepatide's molecular weight explains what that figure tells you about how the medicine behaves in the body.

What 'better' actually means when you factor in safety and suitability

A medicine that works brilliantly for someone else but interacts with your existing treatment, or that you cannot store safely at home, is not better for you. A few practical factors that shift the comparison:

Storage: both Mounjaro and the Wegovy injection pen need refrigeration. If that is a genuine problem (travel, shared living, a job with long shifts away) the oral tablet's room-temperature storage is a meaningful practical advantage. You can check the storage requirements in detail on our Mounjaro storage guide.

Contraception: for women using oral contraceptives, tirzepatide's slowing of gastric emptying means adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase. There is no equivalent instruction for semaglutide. For some people that point alone shifts the preference.

Tolerability: both medicines share a GI-led side-effect profile (nausea, loose stools, appetite changes) most noticeable when starting or increasing doses. Neither is obviously gentler than the other across the board, though individual experience varies considerably.

The treatment overview page sets out how our prescribers approach these decisions and what the private route looks like from first consultation to delivery. Cost context is part of that picture too; you can find an honest breakdown of what UK private treatment typically costs on our Mounjaro cost guide.

A practical check you can do right now

Before speaking to a prescriber, it is worth knowing your current BMI, it takes under a minute with the NHS BMI calculator. Both Mounjaro and Wegovy require a BMI of at least 30 to be licensed for weight management (or 27 with a qualifying health condition), and knowing your number means the consultation can skip the basics and focus on which option genuinely fits you.

Our prescribers review every consultation the same day it arrives, a real clinician reads your answers, not an automated filter. If you have questions specific to your situation before starting, the common Mounjaro questions page covers the ones our team hears most often. And if you want to explore the full clinical profile of tirzepatide before deciding, the tirzepatide treatment page is the place to start.

When you are ready, check your eligibility with a free consultation, there is no obligation, and our prescribers will tell you plainly which option, if any, suits your situation.